The estimated Net Worth of Celia Eckert is at least $3.26 Million dollars as of 11 March 2024. Ms. Eckert owns over 850 units of Xencor Inc stock worth over $960,675 and over the last 5 years she sold XNCR stock worth over $279,486. In addition, she makes $2,023,290 as Vice President, General Counsel und Corporate Secretary at Xencor Inc.
Sign up
Ms. Eckert XNCR stock SEC Form 4 insiders trading
Celia has made over 8 trades of the Xencor Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 850 units of XNCR stock worth $19,975 on 11 March 2024.
The largest trade she's ever made was selling 3,892 units of Xencor Inc stock on 5 March 2024 worth over $91,190. On average, Celia trades about 1,003 units every 110 days since 2020. As of 11 March 2024 she still owns at least 45,465 units of Xencor Inc stock.
You can see the complete history of Ms. Eckert stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Celia Eckert biography
Celia Eckert is Vice President, General Counsel, Corporate Secretary of the Company. Ms. Eckert has served as our General Counsel and Corporate Secretary since September 2019. Ms. Eckert oversees all legal and compliance matters for the Company, including transactions, corporate governance and intellectual property. From October 2016 to August 2019, she held roles at Synthetic Genomics, Inc., including vice president, corporate legal, where she was responsible for licensing and financial transactions, managed litigation and supported corporate legal matters. Prior to Synthetic Genomics, Ms. Eckert served as associate general counsel at Sequenom, Inc. from 2014 to October 2016, and as senior director, legal affairs at Prometheus Laboratories, Inc., which she joined in 2007. At Prometheus, she structured transactions, managed substantial patent litigation and supported the growth of the company’s commercial organization. Earlier in her career, she was an associate at Pillsbury Winthrop Shaw Pittman LLP and at Jones Day. Ms. Eckert received a B.A. in political science from the University of California, Los Angeles and a J.D. from the University of California, Hastings School of Law.
What is the salary of Celia Eckert?
As the Vice President, General Counsel und Corporate Secretary of Xencor Inc, the total compensation of Celia Eckert at Xencor Inc is $2,023,290. There are 2 executives at Xencor Inc getting paid more, with Bassil Dahiyat having the highest compensation of $3,731,510.
How old is Celia Eckert?
Celia Eckert is 48, she's been the Vice President, General Counsel und Corporate Secretary of Xencor Inc since 2019. There are 16 older and 1 younger executives at Xencor Inc. The oldest executive at Xencor Inc is Richard Ranieri, 67, who is the Independent Director.
What's Celia Eckert's mailing address?
Celia's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.
Insiders trading at Xencor Inc
Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford und John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.
What does Xencor Inc do?
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
What does Xencor Inc's logo look like?
Complete history of Ms. Eckert stock trades at Xencor Inc
Xencor Inc executives and stock owners
Xencor Inc executives and other stock owners filed with the SEC include:
-
Bassil Dahiyat,
President, Chief Executive Officer, Founder and Director -
Allen Yang,
Senior Vice President, Chief Medical Officer -
Celia Eckert,
Vice President, General Counsel, Corporate Secretary -
John Desjarlais,
Senior Vice President, Research and Chief Scientific Officer -
John Kuch,
Chief Financial Officer, Vice President -
Dr. Bassil I. Dahiyat Ph.D.,
Co-Founder, CEO, Pres & Director -
Dr. Allen S. Yang M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Dr. John R. Desjarlais,
Sr. VP of Research & Chief Scientific Officer -
Celia E. Eckert J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
John J. Kuch,
Sr. VP & CFO -
A. Bruce Montgomery,
Lead Independent Director -
Dagmar Rosa-Bjorkeson,
Independent Director -
Kurt Gustafson,
Independent Director -
Yujiro Hata,
Independent Director -
Richard Ranieri,
Independent Director -
Kevin Gorman,
Independent Director -
Ellen Feigal,
Independent Director -
Julie Casciani,
Executive Director - Human Resources -
Kirk Rosemark,
Vice President, Regulatory Affairs and Quality Assurance -
Eric Kowack,
Vice President, Program Leadership and Strategic Alliances -
Jeremy Grunstein,
Vice President of Business Development -
Kirk Rosemark RAC,
Sr. VP of Regulatory Affairs & Quality Assurance -
Jennifer Sandoz,
VP of HR -
Charles Liles,
Associate Director and Head of Corp. Communications & Investor Relations -
John S Iii Ronin Capital, L...,
-
Paul A Foster,
Chief Medical Officer -
Barbara Klencke,
Director -
Bruce L A Carter,
Director -
Edgardo Jr Baracchini,
Chief Business Officer -
Robert Jr. Baltera,
Director -
Bart Jan Cornelissen,
SR. VICE PRESIDENT & CFO -
John S Jr Stafford,
10% owner -
Trading, Llc Ronin,
10% owner -
Lloyd A Rowland,
Sr. V.P. and General Counsel -
Atul Saran,
Director -
Harold R Werner,
Director -
Jonathan Fleming,
Director -
John S Iii Stafford,
10% owner -
Capital, Llcstafford John S...,
-
Nancy Valente,
EVP, Chief Development Officer